Dr. Hamlin on Study of Cerdulatinib in Non-Hodgkin Lymphoma

Video

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

Cerdulatinib is an oral dual Syk/JAK inhibitor that is currently being evaluated in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and indolent lymphomas such as follicular lymphoma and peripheral T-cell lymphoma.

This is an open-label, phase II cohort-driven expansion study, preliminary results of which are being presented at the 2017 European Hematology Association Congress.

Related Videos
Jennifer Brown, MD, PhD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania